Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. Circulating tumor cells (CTC) in the blood are hypothesized as the means of systemic tumor spread. Blood obtained from healthy donors and patients with PDAC was therefore subject to size-based CTC-isolation. We additionally c...
Guardado en:
Autores principales: | Birte Kulemann, Stephanie Rösch, Sindy Seifert, Sylvia Timme, Peter Bronsert, Gabriel Seifert, Verena Martini, Jasmina Kuvendjiska, Torben Glatz, Saskia Hussung, Ralph Fritsch, Heiko Becker, Martha B. Pitman, Jens Hoeppner |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3c8818e189834f428dc9c5e17abf9a17 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Metastasis and Tumor Cell Migration of Solid Tumors
por: Jens Hoeppner, et al.
Publicado: (2021) -
Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma
por: Marie-Claire Rittmann, et al.
Publicado: (2021) -
Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics.
por: Vassiliki Kotoula, et al.
Publicado: (2009) -
GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors
por: Aslamuzzaman Kazi, et al.
Publicado: (2018) -
Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity
por: Ian P. Winters, et al.
Publicado: (2017)